<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00546585</url>
  </required_header>
  <id_info>
    <org_study_id>07-0023</org_study_id>
    <nct_id>NCT00546585</nct_id>
  </id_info>
  <brief_title>Safety, Reactogenicity, and Immunogenicity of Inactivated Influenza A/H7/N7 Vaccine in Healthy Adults</brief_title>
  <official_title>A Randomized, Double-Blinded, Placebo-Controlled, Phase I/II, Dose-Ranging Study of the Safety, Reactogenicity, and Immunogenicity of Intramuscular Inactivated Influenza A/H7N7 Vaccine in Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, any adverse events or side effects, and
      the body's immune response to an experimental flu vaccine [Inactivated Influenza A/H7N7
      Vaccine] being given in increasing doses. Researchers will try to find the smallest dose of
      flu vaccine needed to cause antibody responses against the flu virus in both single and
      repeat doses. The study will enroll 125 healthy adults ranging in age from 18 to 40 years
      old. Subjects will be given 2 doses of the vaccine 28 days apart. Study procedures will
      include obtaining a medical history, physical exam, blood sample collections, and use of
      patient memory aids. The volunteers will be in the study for about 7 months.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This randomized, double-blinded, placebo-controlled, dose-ranging, Phase I/II, influenza
      study will compare the safety, reactogenicity, and immunogenicity of increasing doses of
      monovalent subvirion influenza A/H7N7 virus vaccine administered by intramuscular (IM)
      injection to healthy adults. A total of 125 healthy adults ranging from 18 to 40 years old
      will be enrolled at one site for this study. The subjects will be randomized to receive
      saline placebo or 7.5, 15, 45, or 90 mcg of the influenza A/H7N7 vaccine by intramuscular
      (IM) injection in an approximate 1:1:1:1:1 ratio (N=25/vaccine dose group and 25 in the
      placebo group). Subjects will receive 2 doses separated by approximately 28 days. Subjects
      will be observed in the clinic for a minimum of 30 minutes after inoculation. All subjects
      will maintain a memory aid to record oral temperature and systemic and local adverse events
      (AEs) for 7 days after each immunization. Subjects will be contacted by telephone 1-3 days
      after vaccination to assess for the occurrence of AEs, and they will return to the clinic
      between Day 8 and 12 for AE and concomitant medication assessment, a targeted physical
      examination (if indicated), and review of the memory aid. Serum for immunogenicity
      evaluations will be obtained for subjects prior to the first vaccination, at Day 28 prior to
      the second vaccination, and on Days 56 and 208. A Safety Monitoring Committee (SMC) will
      review available 7 day safety data at approximately Day 20 following the first subject
      vaccination before administering the second dose of vaccine to any subjects. The primary
      objectives of the study will be: to determine the dose-related safety of subvirion
      inactivated H7N7 vaccine in healthy adults; to determine the dose-related immunogenicity of
      subvirion inactivated H7N7 vaccine in healthy adults approximately 1 month following receipt
      of 2 doses of vaccine; and to provide information for the selection of the best dose levels
      for further studies. The secondary objective will be to evaluate the dose-related
      immunogenicity and the percent of subjects responding approximately 1 and 7 months after the
      first vaccination. The primary endpoints are: adverse event (AE) or serious adverse event
      (SAE) information (solicited in-clinic and via memory aids, concomitant medications, and
      periodic targeted physical assessment); the proportion of subjects in each dose group
      achieving a serum neutralizing antibody titer of greater than or equal to 40 against the
      influenza A/H7N7 virus 28 days after receipt of the second dose of vaccine (approximately Day
      56); geometric mean titer (GMT) and frequency of 4-fold or greater increases in neutralizing
      antibody titers in each group 1 month after receipt of each dose, and 7 months after receipt
      of the first dose of vaccine; and GMT and frequency of 4-fold or greater increases in serum
      hemagglutination inhibition (HAI) antibody titers in each group 1 month after receipt of each
      dose, and 7 months after receipt of the first dose of vaccine. Participants will be involved
      in study related procedures for approximately 7 months. This study is linked to DMID protocol
      07-0060.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2008</start_date>
  <completion_date type="Actual">February 2009</completion_date>
  <primary_completion_date type="Actual">February 2009</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse event (AE) or serious adverse event (SAE) information (solicited in-clinic and via memory aids, concomitant medications, and periodic targeted physical assessment).</measure>
    <time_frame>Duration of study.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of subjects in each dose group achieving a serum neutralizing antibody titer of greater than or equal to 40 against the influenza A/H7N7 virus.</measure>
    <time_frame>28 days after receipt of the second dose of vaccine (approximately Day 56).</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric mean titer (GMT) and frequency of 4-fold or greater increases in neutralizing antibody titers in each group and serum hemagglutination inhibition (HAI) antibody titers in each group.</measure>
    <time_frame>1 month after receipt of each dose, and 7 months after receipt of the first dose of vaccine.</time_frame>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">126</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>90 mcg of Influenza A/H7N7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>25 subjects to receive 90 mcg of Influenza A/H7N7.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>15 mcg of Influenza A/H7N7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>25 subjects to receive 15 mcg of Influenza A/H7N7.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>7.5 mcg of Influenza A/H7N7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>25 subjects to receive 7.5 mcg of Influenza A/H7N7.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>45 mcg of Influenza A/H7N7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>25 subjects to receive 45 mcg of Influenza A/H7N7.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>25 subjects to receive placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Influenza A/H7N7 Vaccine</intervention_name>
    <description>Monovalent subvirion H7N7 vaccine, 4 dose levels of vaccine, each subject will receive 2 doses (7.5, 15, 45, or 90 micrograms); the same dose will be given at Day 0 and Day 28.</description>
    <arm_group_label>15 mcg of Influenza A/H7N7</arm_group_label>
    <arm_group_label>45 mcg of Influenza A/H7N7</arm_group_label>
    <arm_group_label>7.5 mcg of Influenza A/H7N7</arm_group_label>
    <arm_group_label>90 mcg of Influenza A/H7N7</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Sterile normal saline for injection (0.9%); 0.5 ml volume sodium chloride injection. Subjects will receive 2 doses on Day 0 and Day 28.</description>
    <arm_group_label>Saline placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or non-pregnant female (as indicated by a negative urine pregnancy test
             immediately prior to vaccine administration) between the ages of 18 and 40 years,
             inclusive.

          -  Women of childbearing potential (not surgically sterile or postmenopausal for greater
             than or equal to 1 year) who are at risk of becoming pregnant must agree to practice
             adequate contraception (i.e., barrier method, abstinence, intrauterine devices, and
             licensed hormonal methods) for the entire study period.

          -  Is in good health, as determined by vital signs (heart rate &lt; 100 beats per minute,
             blood pressure: systolic less than or equal to 140 mm Hg and greater than or equal to
             90 mm Hg, diastolic less than or equal to 90 mm Hg; oral temperature &lt; 100 degrees
             Fahrenheit), medical history to ensure stable* medical condition and a targeted
             physical examination based on medical history. (*A stable medical condition is defined
             as no recent change in prescription medication, dose, or frequency of medication in
             the last 3 months and health outcomes of the specific disease are considered to be
             within acceptable limits in the last 6 months. Any change that is due to change of
             health care provider, insurance company, etc, or is done for financial reasons, as
             long as in the same class of medication, will not be considered a violation of the
             inclusion criterion. Any change to prescription medication due to improvement of a
             disease outcome will not be considered a violation of the inclusion criterion.)

          -  Able to understand and comply with planned study procedures.

          -  Provide informed consent prior to initiation of any study procedures and are available
             for all study visits.

        Exclusion Criteria:

          -  Have a known allergy to eggs or other components of the vaccine (including gelatin,
             formaldehyde, octoxinol, aluminum hydroxide, and chicken protein).

          -  Have a positive urine or serum pregnancy test prior to vaccination (if female of
             childbearing potential) or women who are breastfeeding.

          -  Have immunosuppression as a result of an underlying illness or treatment with
             immunosuppressive or cytotoxic drugs, or use of anticancer chemotherapy or radiation
             therapy within the preceding 36 months.

          -  Have an active neoplastic disease or a history of any hematologic malignancy.

          -  Have long-term use of oral steroids, parenteral steroids, or high-dose inhaled
             steroids (&gt;800 micrograms/day of beclomethasone dipropionate or equivalent) within the
             preceding 6 months (nasal and topical steroids are allowed.)

          -  Have a history of receiving immunoglobulin or other blood product within the 3 months
             prior to enrollment in this study.

          -  Have received any other licensed vaccines within 2 weeks (for inactivated vaccines) or
             4 weeks (for live vaccines) prior to vaccination in this study.

          -  Have an acute or chronic medical condition that, in the opinion of the investigator,
             would render vaccination unsafe or would interfere with the evaluation of responses.
             (This includes, but is not limited to: known chronic liver disease, significant renal
             disease, unstable or progressive neurological disorders, diabetes mellitus, and
             transplant recipients).

          -  Have a history of severe reactions following immunization with contemporary influenza
             virus vaccines.

          -  Have an acute illness, including an oral temperature greater than 100.4 degrees
             Fahrenheit, within 1 week of vaccination.

          -  Received an experimental agent (vaccine, drug, biologic, device, blood product, or
             medication) within 1 month prior to vaccination in this study, or expect to receive an
             experimental agent during the 7-month study period.

          -  Plan to enroll in another clinical trial at any time during the study period.

          -  Have any condition that would, in the opinion of the site investigator, place the
             subject at an unacceptable risk of injury or render the subject unable to meet the
             requirements of the protocol.

          -  Have a diagnosis of schizophrenia, Bi-polar disease or other major psychiatric
             diagnosis.

          -  Have been hospitalized for psychiatric illness, history of suicide attempt or
             confinement for danger to self or others.

          -  Are receiving psychiatric drugs*. Subjects who are receiving a single antidepressant
             drug and stable for at least 3 months prior to enrollment, without de-compensating
             symptoms will be allowed to be enrolled in the study.

             * aripiprazole, clozapine, ziprasidone, haloperidol, molindone, loxapine,
             thioridazine, thiothixene, pimozide, fluphenazine, risperidone, mesoridazine,
             quetiapine, trifluoperazine, trifluopromazine, chlorprothixene, chlorpromazine,
             perphenazine, olanzapine, carbamazepine, divalproex sodium, lithium carbonate or
             lithium citrate

          -  Have a known active human immunodeficiency virus, hepatitis B, or hepatitis C
             infection.

          -  Have a history of alcohol or drug abuse in the last 5 years.

          -  Plan to travel outside of the USA in the time between the first vaccination and 56
             days following the first vaccination.

          -  Have a history of Guillain-Barre syndrome.

          -  Have any condition that the investigator believes may interfere with successful
             completion of the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Baylor College of Medicine - Department of Molecular Virology and Microbiology</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Couch RB, Patel SM, Wade-Bowers CL, Ni√±o D. A randomized clinical trial of an inactivated avian influenza A (H7N7) vaccine. PLoS One. 2012;7(12):e49704. doi: 10.1371/journal.pone.0049704. Epub 2012 Dec 11.</citation>
    <PMID>23239968</PMID>
  </results_reference>
  <verification_date>January 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 18, 2007</study_first_submitted>
  <study_first_submitted_qc>October 18, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 19, 2007</study_first_posted>
  <disposition_first_submitted>July 20, 2011</disposition_first_submitted>
  <disposition_first_submitted_qc>July 20, 2011</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">July 22, 2011</disposition_first_posted>
  <last_update_submitted>August 15, 2013</last_update_submitted>
  <last_update_submitted_qc>August 15, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 23, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>influenza, inactivated influenza A/H7N7 vaccine, parent protocol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

